# Tianzhu Ruichang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tianzhu-ruichang

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Total disclosed funding: $9.3M
- Latest round: Series A (May 27, 2021)
- Investors on record: 4

## About

Established in 2016 and based in Beijing, China, Tianzhu Ruichang is a medical technology company that focuses on the research and development of aortic stent graft system.

The company engages in research and developing aortic stent graft system. Its main product is three-branch thoracic aorta stent graft system. The three-branch thoracic aorta stent graft system is suitable for aortic dissection involving the aortic arch, and realizes endovascular repair and treatment of aortic arch lesions.

In the future, the company will advance clinical trials of a universal three-branch integrated thoracic aorta stent graft system.

## Funding rounds

- Series A, May 27, 2021, $9.3M — Cowin Capital, Qiaojing Capital, Tengye Ventures
- Angel, Aug 31, 2017 — Qiaojing Capital, Chiron Ventures

## Investors

- Qiaojing Capital (https://capitalatlas.ai/funds/qiaojing-capital) — Angel, Series A
- Chiron Ventures — Angel
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- Tengye Ventures (https://capitalatlas.ai/funds/tengye-ventures) — Series A